




Fig. 1





Fig. 2

SUBSTITUTE SHEET (RULE 26)



3/28





Fig. 3A

SUBSTITUTE SHEET (RULE 26)

4/28





Fig. 3B

SUBSTITUTE SHEET (RULE 26)

5/28




Fig. 4

6/28




Fig. 5

RM 2-way ANOVA	p-value
Time	0.046
Treatment	0.589
Time*Treatment	0.003

EA-230 effects on plasma creatinine related to pre-surgery kidney function




Fig. 6

EA-230 effects on MDRD related to pre-surgery kidney function.





Fig. 7

Effects of EA-230 on MDRD related to duration of cardiac-pulmonary bypass.



Kidney function as estimated GFR using the MDRD formula over time

Kidney function as estimated GFR using the MDRD formula over time

Fig. 8

No immunomodulatory effects in EASI-study.




Fig. 9

11/28

Effects of EA-230 on length of stay.





Fig. 10

12/28

EA-230 effects on length of stay in hospital by acute kidney injury stage of the RIFLE score per treatment group.



Length of Stay in hospital by stages of acute kidney injury of the RILFE score.

Fig. 11




Fig. 12




Fig. 13





Fig. 14



16/28

Fig. 16

Fig. 15




Fig. 17




Fig. 18




Fig. 19 (a-b)




Fig. 19 (c-d)




Fig. 20 (a-b)




Fig. 20 (c-d-e)




Fig. 21 (a-b-c-d)




Fig. 21 (e-f)




Fig. 22 (a-b)




Fig. 22 (c-d-e)

27/28

Table 1: summary of experiments

Entry		mmol	Added amount								Solubility mmol/mL
			19-1	22-1	23-1	24-1	25-1	26-1	31-1	01-02	
1	citric acid	1.75	500	0.25 mmol	0.5 mmol			0.25 mmol	X	X	>2,75mmol/ 500 uL
Added uL (9g NaCl/L H ₂ O)											
2	maleic acid	1	200 (clear) but crystallized over the weekend	50	50	150	200 (clear)	X	X	X	1 mmol/ 650 uL
3	KHSO ₄	1	200	50	50	100	50	150	150 (clear)	150 (clear)	1 mmol/ 900 uL
4	(+)-tartaric acid	1	200	50	50	50 (clear)	X	X	Some Solids again	50 (clear)	1 mmol/ 400 uL
5	acetic acid	1	200	50	50	150	50 (clear)	X	X	X	1 mmol/ 500 uL
6	adenosine mono- phosphate	0.5	200	100	50	300	200	300	2200	Vial full	<<0,5 mmol/ 3350 uL
7	adenosine	0.5	200	100	50	300	200	300	2200	Vial full	<<0,5 mmol/ 3350 uL

Fig. 23

Table 2: Solubility of different salt of AQGV in 0.9% NaCl.

Acid	Solubility (in 0.9% NaCl)
citric acid	> 5.5 mmol/ mL
maleic acid	1.54 mmol/mL
KHSO ₄	1.11 mmol/mL
(+)-tartaric acid	2.5 mmol/mL
acetic acid	2 mmol/mL
adenosine mono-phosphate	< 0.15 mmol/mL
Adenosine	< 0.15 mmol/mL

Fig. 24